LEO Pharma, Denmark’s oldest healthcare company, announced today the launch of its first innovation lab in North America. Backed by $100M CDN in funding, LEO Innovation Lab will develop new, non-pharmaceutical solutions for people living with psoriasis and partner with the startup community to foster innovation in apps, web platforms, wearables, virtual reality, artificial intelligence, tele-medicine and other advanced technologies.<p>LEO Innovation Lab will focus on areas such as stress, diet, social relationships and healthcare provider interaction.<p>Through its newly announced LEO Ventures initiative, LEO Innovation Lab is also prepared to invest in and give grants to startups to help contribute to finding and developing solutions.<p>Facts about LEO Innovation Lab
●      New innovation lab with 100 million CAD in funding and no profit requirements
●      Does not develop pharmaceutical products, but offers a wide range of other solutions to improve life of people living with psoriasis
●      The timeframe for projects will be 100 days from ideation to beta test
●      Independently operating unit with its own board with key performance metrics focused on making a difference for people living with psoriasis
●      Established by LEO Pharma as part of a long-term strategic decision to put people at the centre
●      LEO Pharma is owned by the LEO Foundation and profits are reinvested in the company<p>For more information contact:<p>Miron Derchansky (PhD, MBA)
Head of Innovation
LEO Innovation Lab – Canada
(647) 284-7922
miron@leoilabs.com
LEO Pharma Launches North American Innovation Lab with $100M CDN in Funding